The Epstein-Barr Virus (EBV) market is rapidly expanding, driven by increased recognition of its association with various diseases, including cancers and autoimmune disorders. EBV, affecting over 90% ...

The Epstein-Barr virus (EBV) is our constant companion, infecting an estimated 90%-95% of adults. Many of us are first infected as children, when the germ may trigger cold and flu symptoms. EBV also ...

Sanakar Swaminathan, M.D., Dinesh Verma, Ph.D. Heart failure drug also inhibits Epstein-Barr virus by targeting a pathway common to all herpesviruses Today, there is only one class of antiviral ...

The oncology community has long been aware of the association between Epstein-Barr virus (EBV) and certain malignancies, including some forms of lymphoma, but targeting these cancers has proven ...

A research team led by Hong Kong Baptist University (HKBU) has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the ...

The antiviral drug, valganciclovir, can lower the levels of Epstein-Barr virus in children with liver transplants, according to a new study. About half of young transplant recipients with detectable ...

A research team has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumors caused by the virus. It is the ...